<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475460</url>
  </required_header>
  <id_info>
    <org_study_id>HeartMate 3 LIS</org_study_id>
    <nct_id>NCT02475460</nct_id>
  </id_info>
  <brief_title>HeartMate 3™ LIS Study</brief_title>
  <acronym>HM 3 LIS</acronym>
  <official_title>Thoratec Corporation HeartMate 3™ Less Invasive Surgery (LIS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thoratec Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a less invasive implantation technique of the&#xD;
      HeartMate 3 Left Ventricular Assist System (HM 3 LVAS) in 10 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the less invasive implantation technique of the HM 3 LVAS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of survival participants</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>HM 3 LIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients implanted with the HM 3 LVAD via less invasive surgical technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Less Invasive Surgery (LIS)</intervention_name>
    <description>Less invasive HM 3 LVAD surgical implant procedure</description>
    <arm_group_label>HM 3 LIS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartMate 3™</intervention_name>
    <description>HM 3 LIS</description>
    <arm_group_label>HM 3 LIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient or legal representative has signed Informed Consent Form (ICF)&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. BSA ≥ 1.2 m2&#xD;
&#xD;
          4. NYHA IIIB or IV, or ACC/AHA Stage D&#xD;
&#xD;
          5. LVEF ≤ 25%&#xD;
&#xD;
          6. CI ≤ 2.2 L/min/m2, while not on inotropes (if Patient is treated with inotropes at&#xD;
             baseline, this does not apply)&#xD;
&#xD;
          7. Patients must also meet one of the following:&#xD;
&#xD;
               -  On optimal medical management (OMM), based on current heart failure practice&#xD;
                  guidelines for at least 45 out of the last 60 days and are failing to respond, OR&#xD;
&#xD;
               -  In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on&#xD;
                  intraaortic balloon pump (IABP) for at least 7 days, OR&#xD;
&#xD;
               -  Inotrope dependent/unable to wean from inotropes OR&#xD;
&#xD;
               -  Listed for transplant&#xD;
&#xD;
          8. Females of child bearing age must agree to use adequate contraception-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease,&#xD;
             obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive&#xD;
             cardiomyopathy&#xD;
&#xD;
          2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of&#xD;
             the Investigator&#xD;
&#xD;
          3. Existence of ongoing mechanical circulatory support (MCS) other than IABP&#xD;
&#xD;
          4. Positive pregnancy test if of childbearing potential&#xD;
&#xD;
          5. Lactating mothers&#xD;
&#xD;
          6. Presence of mechanical aortic cardiac valve&#xD;
&#xD;
          7. History of any organ transplant&#xD;
&#xD;
          8. Platelet count &lt; 100,000 x 103/L (&lt; 100,000/ml)&#xD;
&#xD;
          9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial&#xD;
             issues that are likely to impair compliance with the study protocol and LVAS&#xD;
             management&#xD;
&#xD;
         10. History of confirmed, untreated AAA &gt; 5 cm in diameter&#xD;
&#xD;
         11. Presence of an active, uncontrolled infection&#xD;
&#xD;
         12. Intolerance to anticoagulant or antiplatelet therapies or any other&#xD;
             peri/post-operative therapy that the Investigator will require based upon the&#xD;
             patients' health status&#xD;
&#xD;
         13. Presence of any one of the following risk factors for indications of severe end organ&#xD;
             dysfunction or failure:&#xD;
&#xD;
               -  An INR ≥ 2.5 not due to anticoagulation therapy&#xD;
&#xD;
               -  Total bilirubin &gt; 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver&#xD;
                  cirrhosis&#xD;
&#xD;
               -  History of severe chronic obstructive pulmonary disease (COPD) defined by&#xD;
                  FEV1/FVC &lt; 0.7, or FEV1 &lt;50% predicted&#xD;
&#xD;
               -  Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is&#xD;
                  unresponsive to pharmacologic intervention&#xD;
&#xD;
               -  History of stroke within 90 days prior to enrollment, or a history of&#xD;
                  cerebrovascular disease with significant (&gt; 80%) carotid artery stenosis&#xD;
&#xD;
               -  Serum Creatinine ≥ 221umol/L (2.5 mg/dl) or the need for chronic renal&#xD;
                  replacement therapy&#xD;
&#xD;
               -  Significant peripheral vascular disease (PVD) accompanied by rest pain or&#xD;
                  extremity ulceration&#xD;
&#xD;
         14. Aortic valve regurgitation &gt; grade 1&#xD;
&#xD;
         15. Pre albumin &lt; 150 mg/L, or Albumin &lt; 30g/L (3 g/dL)&#xD;
&#xD;
         16. Planned Bi-VAD support prior to enrollment&#xD;
&#xD;
         17. Patient has known hypo or hyper coagulable states such as disseminated intravascular&#xD;
             coagulation and heparin induced thrombocytopenia&#xD;
&#xD;
         18. Planned concomitant intra-cardiac cardiac surgery&#xD;
&#xD;
         19. Thrombus formation in the atrium or left ventricle identified by echocardiogram&#xD;
&#xD;
         20. Previous sternotomy or left-sided thoracotomy&#xD;
&#xD;
         21. Participation in any other clinical investigation that is likely to confound study&#xD;
             results or affect the study&#xD;
&#xD;
         22. Any condition other than HF that could limit survival to less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Damme, BSN, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Thoratec Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Clinical and Experimental Medicine (IKEM)</name>
      <address>
        <city>Prague</city>
        <zip>4</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HeartMate 3</keyword>
  <keyword>LVAS</keyword>
  <keyword>LVAD</keyword>
  <keyword>Heart-assist Devices</keyword>
  <keyword>Advanced</keyword>
  <keyword>Ventricular Dysfunction</keyword>
  <keyword>refractory left ventricular</keyword>
  <keyword>Thoratec Corporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

